Physician profile
John Tully
NPI 1265619993
$71,003.40
in general payments reported to CMS, 2019-2025
32 companies · $68K in 2025
The $68K reported for 2025 was more than what 98% of Gastroenterology (Internal Medicine) providers received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $509 · 2021: $415 · 2022: $623 · 2023: $1,065 · 2024: $891 · 2025: $68K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Grant: $66K · Food and Beverage: $3,457.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Grant | $66,000.00 |
| Food and Beverage | $3,457.29 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Madrigal Pharmaceuticals | $66,257.30 | 2024-2025 | Rezdiffra, Resmetirom |
| Abbvie INC. | $1,395.94 | 2019-2025 | Rinvoq, Skyrizi, Linzess |
| Pfizer INC. | $445.40 | 2019-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $391.28 | 2019-2025 | Entyvio, Eohilia, Gattex |
| Janssen Scientific Affairs, LLC | $348.04 | 2019-2021 | |
| Qol Medical, LLC | $222.83 | 2022-2025 | Sucraid, Sucraid |
| Genzyme Corporation | $204.68 | 2022-2024 | |
| Phathom Pharmaceuticals, INC. | $187.16 | 2024-2025 | Voquezna |
| Gilead Sciences, INC. | $150.28 | 2019-2025 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $145.16 | 2019-2025 | Xifaxan |
| Merck Sharp & Dohme LLC | $129.04 | 2021-2024 | Dificid |
| Nestle Healthcare Nutrition INC. | $119.65 | 2021-2023 | |
| Janssen Biotech, INC. | $112.39 | 2019-2024 | Stelara |
| Celgene Corporation | $98.50 | 2021-2023 | Zeposia |
| Boston Scientific Corporation | $91.39 | 2023 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $82.01 | 2019-2023 | Ocaliva |
| Apollo Endosurgery US INC | $68.88 | 2023 | Orbera Intragastric Balloon System |
| Ipsen Biopharmaceuticals, INC | $64.07 | 2024-2025 | Iqirvo |
| Aimmune Therapeutics, INC. | $63.72 | 2024-2025 | Zenpep |
| Ardelyx, INC. | $54.80 | 2022-2024 | Ibsrela |
| Organon LLC | $46.23 | 2023-2024 | Renflexis |
| Ucb, INC. | $45.97 | 2019 | |
| Ferring Pharmaceuticals INC. | $41.78 | 2021-2023 | Rebyota |
| Amgen INC. | $38.62 | 2023 | Amjevita, Avsola |
| Boehringer Ingelheim Pharmaceuticals, INC. | $36.08 | 2023-2024 | Cyltezo |
| Evoke Pharma, INC. | $32.48 | 2023-2025 | Gimoti |
| Lilly USA, LLC | $31.21 | 2025 | Omvoh |
| Regeneron Healthcare Solutions, INC. | $28.59 | 2025 | Dupixent |
| Braintree Laboratories, INC. | $25.86 | 2022 | |
| Alexion Pharmaceuticals, INC. | $21.14 | 2019 | |
| Shionogi INC | $11.82 | 2019 | |
| Allergan, INC. | $11.10 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Tully listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.